- Home
- ESCA vs DRUG Comparison
ESCA vs DRUG Comparison
Compare ESCA & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESCA
- DRUG
- Stock Information
- Founded
- ESCA 1922
- DRUG 2019
- Country
- ESCA United States
- DRUG United States
- Employees
- ESCA N/A
- DRUG N/A
- Industry
- ESCA Recreational Games/Products/Toys
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ESCA Consumer Discretionary
- DRUG Health Care
- Exchange
- ESCA Nasdaq
- DRUG Nasdaq
- Market Cap
- ESCA 209.5M
- DRUG 233.2M
- IPO Year
- ESCA N/A
- DRUG N/A
- Fundamental
- Price
- ESCA $13.90
- DRUG $27.31
- Analyst Decision
- ESCA
- DRUG Strong Buy
- Analyst Count
- ESCA 0
- DRUG 6
- Target Price
- ESCA N/A
- DRUG $83.25
- AVG Volume (30 Days)
- ESCA 16.8K
- DRUG 19.6K
- Earning Date
- ESCA 07-24-2025
- DRUG 08-13-2025
- Dividend Yield
- ESCA 4.44%
- DRUG N/A
- EPS Growth
- ESCA 9.37
- DRUG N/A
- EPS
- ESCA 0.99
- DRUG N/A
- Revenue
- ESCA $249,685,000.00
- DRUG N/A
- Revenue This Year
- ESCA N/A
- DRUG N/A
- Revenue Next Year
- ESCA N/A
- DRUG N/A
- P/E Ratio
- ESCA $13.95
- DRUG N/A
- Revenue Growth
- ESCA N/A
- DRUG N/A
- 52 Week Low
- ESCA $12.53
- DRUG $0.93
- 52 Week High
- ESCA $16.99
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ESCA 43.01
- DRUG 41.95
- Support Level
- ESCA $13.33
- DRUG $27.69
- Resistance Level
- ESCA $14.46
- DRUG $28.74
- Average True Range (ATR)
- ESCA 0.50
- DRUG 1.29
- MACD
- ESCA -0.08
- DRUG 0.14
- Stochastic Oscillator
- ESCA 27.40
- DRUG 39.29
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.